§ Claim under review · Mixed
"In a Spinogenix phase 2a trial of 24 people with mild-to-moderate Alzheimer's, the 300 mg tazbentetol (SPG302) treatment group showed an average improvement of more than 2.5 points on the SMMSE cognitive assessment compared with placebo within four weeks"
Verdict
Mostly accurate
Confidence
HighSummary
This one checks out as a description of what the company reported. Spinogenix did run a phase 2a trial in Australia with 24 people who had mild-to-moderate Alzheimer's, and in December 2025 it reported that the 300 mg group scored more than 2.5 points higher on the standardized Mini-Mental State Exam than placebo after four weeks. The July 2026 follow-up press release and the 72-year-old case study described in the post are also real. The important context the post leaves out is scale and status: the 300 mg comparison involved roughly eight or nine people on the drug versus about four on placebo, the results have not been published in a peer-reviewed journal, another key measure in the same trial was not statistically significant, and the lower 150 mg dose reportedly showed no clinical effect. The 84-week follow-up had no placebo group, so improvement over time cannot be separated from expectancy, repeated-testing effects, or the fact that patients doing poorly tend to drop out. The headline on the image, saying the drug "restored memory," goes well beyond what a small group-level score difference can show. This is an early signal worth watching, not a demonstrated treatment, and only a larger controlled trial can settle it.
The readings
key figures from the evidenceSMMSE improvement, 300 mg vs placebo at 4 weeks
total enrollment in Spinogenix phase 2a trial
Why this verdict
Evidence
The specific number in the claim traces to a real, identifiable source and is reproduced faithfully. Spinogenix's December 8, 2025 press release, reporting topline results for the 300 mg dose presented at the CTAD conference on December 4, 2025, states a greater than 2.5 point average increase in SMMSE within four weeks versus placebo, with p < 0.05. The Alzheimer's Drug Discovery Foundation's independent Cognitive Vitality report repeats this same figure and attributes it to the same press release. Clinical Trials Arena independently reported that patients on the high (300 mg) dose showed the greater than 2.5 point SMMSE advantage over placebo within four weeks. The trial's lead investigator, neurologist Bruce Brew, described the week-4 MMSE improvement of around 2.5-plus points as "quite dramatic" in a June 2026 interview.
The trial (NCT06427668) is real: a randomized, double-blind, placebo-controlled phase 2a study in Australia enrolling 24 patients with mild-to-moderate AD (MMSE 16-26), randomized 2:1 to active drug or placebo across two dose cohorts (150 mg and 300 mg), beginning with a four-week placebo-controlled period followed by a 24-week open-label extension, with an option to continue a further 52 weeks at 300 mg.
The July 2026 follow-up is also real. Spinogenix announced on July 14, 2026 extended data from patients who continued under a compassionate use Special Access Scheme, stating that group SMMSE data support continued benefit beyond one year, with some patients remaining improved over baseline at 84 weeks. The 72-year-old case study is accurately described: NeurologyLive reports her caregiver observed regained ability to read books, follow movies, and recall storylines within three months of starting 300 mg, alongside a 4 to 6 point SMMSE increase and a 2.5 point CDR-SB decrease, with SMMSE remaining above baseline at her most recent visit at 81 weeks.
Findings
✓ What's accurate 8
- The trial exists and is registered (NCT06427668).
- The total enrollment figure of 24 people with mild-to-moderate Alzheimer's is correct.
- The 300 mg dose attribution is correct. The company's topline release was specifically for the 300 mg dose.
- The ">2.5 points on SMMSE versus placebo within four weeks" figure is reproduced accurately from the source, including the placebo comparator and the four-week timeframe.
- The company reported p < 0.05 for this comparison.
- The July 2026 84-week follow-up press release exists and says what the post says it says.
- The 72-year-old caregiver case study is accurately described.
- The post's caption does include real caveats: it states the findings are preliminary, company-reported, from a small study, that the extended follow-up had no placebo group, and that larger controlled trials are needed.
≈ What's misleading 7
- Exaggeration (image headline): "A new drug restored memory in alzheimer's patients in just 4 weeks!" overstates the evidence. A group-level MMSE difference of 2.5 points in a handful of patients is not demonstrated memory restoration. The MMSE is a 30-point global screening instrument, not a memory test. This headline is the part of the post most likely to be seen and shared.
- Omitted qualifier (scale of the evidence): the claim says "24 people," which sounds larger than the actual comparison. The 300 mg result derives from roughly 8 or 9 drug patients versus roughly 4 placebo patients. At that size, a 2.5 point difference can easily be driven by one or two individuals, and a nominal p < 0.05 in a small exploratory trial with multiple endpoints carries limited weight.
- Omitted qualifier (evidence status): the finding comes from a company press release and conference presentation, not a peer-reviewed publication with full data, confidence intervals, or independent review. Neither the claim nor the on-image text says this. The caption says "company-reported" but does not say unpublished or non-peer-reviewed.
- Selective reporting: the same trial's CDR-SB result at four weeks was not statistically significant, and the 150 mg dose reportedly showed no clinical effect. Neither is mentioned. A drug that works at one dose but not a nearby dose is a signal that warrants caution, not confidence.
- Temporal overreach (secondary claim): presenting an uncontrolled compassionate use extension at 84 weeks as evidence of durable benefit. Without a control arm, expectancy effects, practice effects on repeated MMSE testing, and survivor bias (only patients doing well tend to stay on treatment) cannot be excluded.
- Anecdote presented as outcome: the 72-year-old case is a caregiver-reported single case selected by the sponsor for presentation. It is illustrative, not evidence of efficacy.
- Commercial context: the caption pivots to a supplement affiliate link in the account bio. The Alzheimer's research news functions partly as an audience hook for an unrelated commercial offer.
? What's uncertain 6
- The exact number of participants in the 300 mg drug and placebo arms at week 4. Sources report cohort 1 as either 12 or 13 patients; the precise split was not found in any public document.
- Whether the ">2.5" difference reflects improvement in the treated group, decline in the placebo group, or both. Baseline and endpoint means by arm were not located.
- Confidence intervals, effect size precision, and the statistical model used. Not disclosed publicly.
- Whether the p < 0.05 was adjusted for multiple comparisons across the several primary endpoints listed. Not disclosed.
- How many patients contributed to the 84-week group data. The press release says "some patients" without a number.
- Whether full phase 2a results have since been peer-reviewed. I found no such publication.
Sources
7 of 8 linked to recordsSpinogenix press release, Dec 8, 2025, topline phase 2a results
Spinogenix press release, July 14, 2026, 84-week extended data
Alzheimer's Drug Discovery Foundation, Cognitive Vitality "SPG302 (Tazbentetol)" researcher report
Alzforum therapeutics database entry, "Tazbentetol"
NeurologyLive, "Tazbentetol Shows Durable Cognitive Benefit Through 84 Weeks" (July 29, 2026)
NeurologyLive interview with trial investigator Bruce Brew (June 30, 2026)
Clinical Trials Arena (Dec 8, 2025)
Practical Neurology (Dec 10, 2025)